Cancer Biology and Translational Studies
Functional miRNA Screening Identifies Wide-ranging Antitumor Properties of miR-3622b-5p and Reveals a New Therapeutic Combination Strategy in Ovarian Tumor Organoids
Mégane Vernon, Bernard Lambert, Matthieu Meryet-Figuière, Emilie Brotin, Louis-Bastien Weiswald, Hippolyte Paysant, Nicolas Vigneron, Anaïs Wambecke, Edwige Abeilard, Florence Giffard, Marie-Hélène Louis, Cécile Blanc-Fournier, Pascal Gauduchon, Laurent Poulain and Christophe Denoyelle
Mégane Vernon
1Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.
2UNICANCER, Cancer Center François Baclesse, Caen, France.
Bernard Lambert
1Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.
2UNICANCER, Cancer Center François Baclesse, Caen, France.
3CNRS, Normandy Regional Delegation, Caen, France.
Matthieu Meryet-Figuière
1Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.
2UNICANCER, Cancer Center François Baclesse, Caen, France.
Emilie Brotin
1Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.
2UNICANCER, Cancer Center François Baclesse, Caen, France.
4ImpedanCELL core facility, Federative Structure 4206 ICORE, UNICAEN, Caen, France.
Louis-Bastien Weiswald
1Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.
2UNICANCER, Cancer Center François Baclesse, Caen, France.
Hippolyte Paysant
1Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.
2UNICANCER, Cancer Center François Baclesse, Caen, France.
Nicolas Vigneron
1Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.
2UNICANCER, Cancer Center François Baclesse, Caen, France.
Anaïs Wambecke
1Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.
2UNICANCER, Cancer Center François Baclesse, Caen, France.
Edwige Abeilard
1Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.
2UNICANCER, Cancer Center François Baclesse, Caen, France.
4ImpedanCELL core facility, Federative Structure 4206 ICORE, UNICAEN, Caen, France.
Florence Giffard
1Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.
2UNICANCER, Cancer Center François Baclesse, Caen, France.
Marie-Hélène Louis
1Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.
2UNICANCER, Cancer Center François Baclesse, Caen, France.
Cécile Blanc-Fournier
1Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.
2UNICANCER, Cancer Center François Baclesse, Caen, France.
5Biopathology Department, UNICANCER, Cancer Center F. Baclesse, Caen, France.
Pascal Gauduchon
1Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.
2UNICANCER, Cancer Center François Baclesse, Caen, France.
Laurent Poulain
1Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.
2UNICANCER, Cancer Center François Baclesse, Caen, France.
4ImpedanCELL core facility, Federative Structure 4206 ICORE, UNICAEN, Caen, France.
Christophe Denoyelle
1Normandie Univ, UNICAEN, Inserm U1086 ANTICIPE (Interdisciplinary Research Unit for the Prevention and Treatment of Cancer), Biology and Innovative Therapies of Ovarian Cancers (BioTICLA), Caen, France.
2UNICANCER, Cancer Center François Baclesse, Caen, France.
4ImpedanCELL core facility, Federative Structure 4206 ICORE, UNICAEN, Caen, France.
DOI: 10.1158/1535-7163.MCT-19-0510 Published July 2020

This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
July 2020
Volume 19, Issue 7
Volume 19, Issue 7
Functional miRNA Screening Identifies Wide-ranging Antitumor Properties of miR-3622b-5p and Reveals a New Therapeutic Combination Strategy in Ovarian Tumor Organoids
Mégane Vernon, Bernard Lambert, Matthieu Meryet-Figuière, Emilie Brotin, Louis-Bastien Weiswald, Hippolyte Paysant, Nicolas Vigneron, Anaïs Wambecke, Edwige Abeilard, Florence Giffard, Marie-Hélène Louis, Cécile Blanc-Fournier, Pascal Gauduchon, Laurent Poulain and Christophe Denoyelle
Mol Cancer Ther July 1 2020 (19) (7) 1506-1519; DOI: 10.1158/1535-7163.MCT-19-0510
Functional miRNA Screening Identifies Wide-ranging Antitumor Properties of miR-3622b-5p and Reveals a New Therapeutic Combination Strategy in Ovarian Tumor Organoids
Mégane Vernon, Bernard Lambert, Matthieu Meryet-Figuière, Emilie Brotin, Louis-Bastien Weiswald, Hippolyte Paysant, Nicolas Vigneron, Anaïs Wambecke, Edwige Abeilard, Florence Giffard, Marie-Hélène Louis, Cécile Blanc-Fournier, Pascal Gauduchon, Laurent Poulain and Christophe Denoyelle
Mol Cancer Ther July 1 2020 (19) (7) 1506-1519; DOI: 10.1158/1535-7163.MCT-19-0510
Jump to section
Advertisement